Baxter, BioMerieux enter distribution deal | NeuMoDx acquired by Qiagen | COVID-19 antigen test released by Abbott in France
September 23, 2020
AACC SmartBrief
SIGN UP ⋅   SHARE
ADVERTISEMENT
Business Perspective
Baxter has entered an exclusive distribution agreement with BioMerieux for the latter's NEPHROCLEAR CCL14 test, a kidney injury diagnostic test that is in development. Baxter will be the test's exclusive distributor in the US and Europe.
Full Story: Seeking Alpha (free registration) (9/16) 
LinkedIn Twitter Facebook Email
Qiagen has bought the remaining 80.1% of diagnostics instrument firm NeuMoDx for $248 million in cash, after purchasing a 19.9% stake in 2018. "NeuMoDx has built an unparalleled platform that has demonstrated superior value during the coronavirus pandemic. This will expand Qiagen's portfolio of automated testing solutions and provide another driver for future growth," Qiagen CEO Thierry Bernard said.
Full Story: BioWorld (free content) (9/18) 
LinkedIn Twitter Facebook Email
The Panbio COVID-19 Ag Rapid Test has been released by Abbott in France. "This rapid and portable nasopharyngeal swab test device is a very useful tool for supporting public health strategies in France, such as contact case tracing and large-scale testing campaigns across France," Abbott France Sales Director Jean-Baptiste Nivet said.
Full Story: BioWorld (free content) (9/18) 
LinkedIn Twitter Facebook Email
The Elecsys Anti-SARS-CoV-2 S antibody test has been released by Roche. "The new quantitative Elecsys antibody test can play a pivotal role in vaccine clinical trials as well as helping clinicians assess patients' immune response," said CEO Thomas Schinecker.
Full Story: Seeking Alpha (free registration) (9/18) 
LinkedIn Twitter Facebook Email
Hoth Therapeutics and the George Washington University will collaborate to develop an in vitro nanohole array-based diagnostic device that uses a plasmonic system to immediately detect SARS-CoV-2 using a mobile device.
Full Story: Seeking Alpha (free registration) (9/21) 
LinkedIn Twitter Facebook Email
Science Briefs
Researchers in France found that SARS-CoV-2 infection was associated with an increased rate of Kawasaki disease in youths. The findings, published in The Lancet Child and Adolescent Health, also showed that those with severe Kawasaki disease were more likely to require admission to the intensive care unit, need combination therapy with inotrope treatment and have myocarditis.
Full Story: 2 Minute Medicine (9/16) 
LinkedIn Twitter Facebook Email
Practice Briefs
European regulators have given CE mark approval to DiaSorin for its Simplexa COVID-19 Direct assay for the testing of saliva samples to identify people with COVID-19.
Full Story: FDAnews (9/21) 
LinkedIn Twitter Facebook Email
Business/Corporate Briefs
The Biomedical Advanced Research and Development Authority has given $12.85 million to Ortho Clinical Diagnostics to aid in the development of its COVID-19 antigen test and to help obtain regulatory clearance for its total and IgG antibody tests that have received emergency use authorization.
Full Story: Drug Discovery & Development (9/22) 
LinkedIn Twitter Facebook Email
Sharing AACC SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
SHARE
Or copy and share your personalized link:
smartbrief.com/aacc/?referrerId=eSriBJbAIQ
LEARN MORE ABOUT AACC:
AACC Homepage | AACC Membership | Annual Meeting
Clinical Laboratory News | Clinical Chemistry | JALM
 
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004